PDCD1 and non-small cell lung carcinoma: Based on the hypothesis that gut microbiota‐derived metabolites spread from their original location and impact the systemic levels of metabolites, we combined gut microbiome analysis with faecal metabolomics and plasma metabolomics in an NSCLC anti‐PD‐1 clinical study.